Abstract
Purpose: This report discusses the case of an 86-year-old man with a full-thickness macular hole (FTMH) secondary to polypoidal choroidal vasculopathy (PCV) treated with bevacizumab. Methods: A case report is presented. Results: An 86-year-old man presented with a 5-month history of metamorphopsia and decreased vision in his right eye and was found to have active exudation secondary to PCV with a concurrent FTMH. After 4 treatments with intravitreal bevacizumab, the FTMH resolved without surgical intervention. Conclusions: The patient’s FTMH resolved with solely pharmacologic treatment as a result of treating his PCV with intravitreal bevacizumab. Macular hole formation secondary to PCV is a rare finding, but may be successfully treated with pharmacologic therapy without surgical intervention.
Original language | English (US) |
---|---|
Pages (from-to) | 433-436 |
Number of pages | 4 |
Journal | Journal of VitreoRetinal Diseases |
Volume | 4 |
Issue number | 5 |
DOIs | |
State | Published - Sep 1 2020 |
Externally published | Yes |
Keywords
- bevacizumab
- full-thickness macular hole
- macular hole
- polypoidal choroidal vasculopathy
ASJC Scopus subject areas
- Ophthalmology